vs

Side-by-side financial comparison of COMPUGEN LTD (CGEN) and CVD EQUIPMENT CORP (CVV). Click either name above to swap in a different company.

CVD EQUIPMENT CORP is the larger business by last-quarter revenue ($5.0M vs $3.5M, roughly 1.4× COMPUGEN LTD). CVD EQUIPMENT CORP runs the higher net margin — -25.6% vs -410.1%, a 384.5% gap on every dollar of revenue. On growth, CVD EQUIPMENT CORP posted the faster year-over-year revenue change (-33.2% vs -61.8%). CVD EQUIPMENT CORP produced more free cash flow last quarter ($396.0K vs $-18.8M).

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big compan...

CVD Equipment Corp designs, manufactures and supplies custom chemical vapor deposition systems, thermal processing equipment and related process control solutions. Its offerings cater to semiconductor manufacturing, renewable energy, aerospace, and advanced materials research segments, serving commercial and academic customers globally.

CGEN vs CVV — Head-to-Head

Bigger by revenue
CVV
CVV
1.4× larger
CVV
$5.0M
$3.5M
CGEN
Growing faster (revenue YoY)
CVV
CVV
+28.5% gap
CVV
-33.2%
-61.8%
CGEN
Higher net margin
CVV
CVV
384.5% more per $
CVV
-25.6%
-410.1%
CGEN
More free cash flow
CVV
CVV
$19.2M more FCF
CVV
$396.0K
$-18.8M
CGEN

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CGEN
CGEN
CVV
CVV
Revenue
$3.5M
$5.0M
Net Profit
$-14.5M
$-1.3M
Gross Margin
22.2%
Operating Margin
-475.1%
-27.2%
Net Margin
-410.1%
-25.6%
Revenue YoY
-61.8%
-33.2%
Net Profit YoY
-54.7%
-1060.6%
EPS (diluted)
$-0.16
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CGEN
CGEN
CVV
CVV
Q4 25
$5.0M
Q3 25
$7.4M
Q2 25
$3.5M
$5.1M
Q1 25
$8.3M
Q4 24
$7.4M
Q3 24
$8.2M
Q2 24
$9.3M
$6.3M
Q1 24
$2.6M
$4.9M
Net Profit
CGEN
CGEN
CVV
CVV
Q4 25
$-1.3M
Q3 25
$384.0K
Q2 25
$-14.5M
$-1.1M
Q1 25
$360.0K
Q4 24
$132.0K
Q3 24
$203.0K
Q2 24
$-9.4M
$-761.0K
Q1 24
$7.3M
$-1.5M
Gross Margin
CGEN
CGEN
CVV
CVV
Q4 25
22.2%
Q3 25
32.7%
Q2 25
21.0%
Q1 25
32.4%
Q4 24
26.3%
Q3 24
21.5%
Q2 24
60.5%
24.3%
Q1 24
17.9%
16.2%
Operating Margin
CGEN
CGEN
CVV
CVV
Q4 25
-27.2%
Q3 25
4.2%
Q2 25
-475.1%
-22.3%
Q1 25
3.2%
Q4 24
0.4%
Q3 24
0.9%
Q2 24
-128.5%
-14.2%
Q1 24
-33.0%
Net Margin
CGEN
CGEN
CVV
CVV
Q4 25
-25.6%
Q3 25
5.2%
Q2 25
-410.1%
-20.8%
Q1 25
4.3%
Q4 24
1.8%
Q3 24
2.5%
Q2 24
-101.4%
-12.0%
Q1 24
284.0%
-29.9%
EPS (diluted)
CGEN
CGEN
CVV
CVV
Q4 25
$-0.19
Q3 25
$0.06
Q2 25
$-0.16
$-0.15
Q1 25
$0.05
Q4 24
$0.02
Q3 24
$0.03
Q2 24
$-0.10
$-0.11
Q1 24
$89505618.00
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CGEN
CGEN
CVV
CVV
Cash + ST InvestmentsLiquidity on hand
$35.3M
$8.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$50.3M
$24.7M
Total Assets
$106.5M
$27.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CGEN
CGEN
CVV
CVV
Q4 25
$8.7M
Q3 25
$8.4M
Q2 25
$35.3M
$7.0M
Q1 25
$10.2M
Q4 24
$12.6M
Q3 24
$10.0M
Q2 24
$44.6M
$10.0M
Q1 24
$39.3M
$11.9M
Total Debt
CGEN
CGEN
CVV
CVV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$268.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CGEN
CGEN
CVV
CVV
Q4 25
$24.7M
Q3 25
$25.8M
Q2 25
$50.3M
$25.2M
Q1 25
$26.0M
Q4 24
$25.4M
Q3 24
$25.0M
Q2 24
$58.3M
$24.5M
Q1 24
$65.6M
$25.0M
Total Assets
CGEN
CGEN
CVV
CVV
Q4 25
$27.5M
Q3 25
$29.8M
Q2 25
$106.5M
$29.9M
Q1 25
$31.1M
Q4 24
$31.7M
Q3 24
$31.8M
Q2 24
$110.2M
$33.8M
Q1 24
$121.3M
$35.4M
Debt / Equity
CGEN
CGEN
CVV
CVV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.01×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CGEN
CGEN
CVV
CVV
Operating Cash FlowLast quarter
$-18.6M
$397.0K
Free Cash FlowOCF − Capex
$-18.8M
$396.0K
FCF MarginFCF / Revenue
-530.8%
8.0%
Capex IntensityCapex / Revenue
6.5%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CGEN
CGEN
CVV
CVV
Q4 25
$397.0K
Q3 25
$1.4M
Q2 25
$-18.6M
$-3.2M
Q1 25
$-2.3M
Q4 24
$2.3M
Q3 24
$32.0K
Q2 24
$39.7M
$-1.7M
Q1 24
$-2.0M
Free Cash Flow
CGEN
CGEN
CVV
CVV
Q4 25
$396.0K
Q3 25
Q2 25
$-18.8M
$-3.2M
Q1 25
$-2.3M
Q4 24
$2.1M
Q3 24
$-5.0K
Q2 24
$39.7M
$-1.8M
Q1 24
$-2.1M
FCF Margin
CGEN
CGEN
CVV
CVV
Q4 25
8.0%
Q3 25
Q2 25
-530.8%
-62.1%
Q1 25
-27.7%
Q4 24
28.8%
Q3 24
-0.1%
Q2 24
428.3%
-29.0%
Q1 24
-42.9%
Capex Intensity
CGEN
CGEN
CVV
CVV
Q4 25
0.0%
Q3 25
0.0%
Q2 25
6.5%
0.1%
Q1 25
0.5%
Q4 24
1.5%
Q3 24
0.5%
Q2 24
0.4%
1.8%
Q1 24
1.4%
Cash Conversion
CGEN
CGEN
CVV
CVV
Q4 25
Q3 25
3.53×
Q2 25
Q1 25
-6.28×
Q4 24
17.05×
Q3 24
0.16×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CGEN
CGEN

Segment breakdown not available.

CVV
CVV

Transferred Over Time$3.8M76%
Transferred At Point In Time$1.2M24%

Related Comparisons